News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

New Patent Application Published for Prous Institute's Multi Kinase Inhibitors (WO 2012013691 A1)

Compounds developed using Prous Institute Symmetry® Drug Discovery Platform open new avenues in cancer treatment

Prous Institute for Biomedical Research has announced the recent publishing of its new WIPO patent application. The cited compounds figured among the new magnolol and honokiol derivatives obtained at the Prous Institute for Biomedical Research that have shown inhibitory activity against multiple protein kinases, including epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase Src, cyclin-dependent protein kinase (CDK2), protein kinase C (PKC) and mitogen-activated protein kinase (MAPK 1). The compounds' antiproliferative activity (IC50 = 0.9-4.6 mcM) has been demonstrated in brain, colon, liver, ovary, prostate and breast tumor cell lines, as well as melanoma and leukemia cell lines. These novel compounds have potential to suppress tumor growth and/or prevent recurrence of metastasis. In vivo efficacy of the compounds has been proven using tumor xenografts models. Furthermore, analgesic activity of claimed compounds has been observed in experimental animal models of pain (WO 2012013691).

The new compounds have been developed using Prous Institute's proprietary drug discovery platform known as Prous Institute SYMMETRY®.  These compounds are the result of the platform's mechanism of action screening technologies (used to predict both on-target and off-target activities), and their applied use in drug discovery opportunities in the field of natural products.